Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.

[1]  L. Salomon,et al.  Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. , 2011, European urology.

[2]  E. Colás,et al.  PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine , 2010, The Prostate.

[3]  A. Bjartell,et al.  PCA3 as a diagnostic marker for prostate cancer: A validation study on a Swedish patient population , 2010, Scandinavian journal of urology and nephrology.

[4]  G. Andriole,et al.  PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. , 2010, The Journal of urology.

[5]  T. D. de Reijke,et al.  External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. , 2010, European urology.

[6]  A. Haese*,et al.  The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free‐to‐total prostate‐specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies? , 2010, BJU international.

[7]  R. V. D. van den Bergh,et al.  Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. , 2010, European urology.

[8]  A. Haese*,et al.  Follow‐up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer? , 2010, BJU international.

[9]  Jian Wang,et al.  Targeting Gene‐ViroTherapy for prostate cancer by DD3‐driven oncolytic virus‐harboring interleukin‐24 gene , 2010, International journal of cancer.

[10]  R. Vessella,et al.  Molecular assays for the detection of prostate tumor derived nucleic acids in peripheral blood , 2010, Molecular Cancer.

[11]  J. Irani,et al.  Immediate impact of ultrasound-guided prostate biopsies on PCA3 score. , 2010, European urology.

[12]  A. Stenzl,et al.  Interpretation of the Prostate Cancer Gene 3 in Reference to the Individual Clinical Background: Implications for Daily Practice , 2010, Urologia Internationalis.

[13]  A. Partin,et al.  Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. , 2010, The Journal of urology.

[14]  M. Babjuk,et al.  Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis. , 2010, Anticancer research.

[15]  A. Miller,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[16]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[17]  J. Schalken,et al.  Preliminary evaluation of the effect of dutasteride on PCA3 in post‐DRE urine sediments: A randomized, open‐label, parallel‐group pilot study , 2009, The Prostate.

[18]  W. Ellis,et al.  Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. , 2009, European urology.

[19]  John T. Wei,et al.  Rational approach to implementation of prostate cancer antigen 3 into clinical care , 2009, Cancer.

[20]  B. Ouyang,et al.  A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer. , 2009, The Journal of urology.

[21]  J. Schalken,et al.  The use of PCA3 in the diagnosis of prostate cancer , 2009, Nature Reviews Urology.

[22]  J. Oppenheimer,et al.  PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting. , 2009, Urology.

[23]  I. Bisson,et al.  Hedgehog signalling in androgen independent prostate cancer. , 2008, European urology.

[24]  Mesut Remzi,et al.  Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. , 2008, European urology.

[25]  S. Srivastava,et al.  PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. , 2008, The Journal of urology.

[26]  Robin J Leach,et al.  Predicting prostate cancer risk through incorporation of prostate cancer gene 3. , 2008, The Journal of urology.

[27]  L. Goulart,et al.  The -786T>C promoter polymorphism of the NOS3 gene is associated with prostate cancer progression , 2008, BMC Cancer.

[28]  J. Witjes,et al.  Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results , 2008, The Prostate.

[29]  P. Troncoso,et al.  PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. , 2008, The Journal of urology.

[30]  W. Ellis,et al.  PCA3: a molecular urine assay for predicting prostate biopsy outcome. , 2008, The Journal of urology.

[31]  W. Ellis,et al.  A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[32]  Jianjun Yu,et al.  A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. , 2008, Cancer research.

[33]  Glenn Heller,et al.  Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer , 2007, Clinical Cancer Research.

[34]  G. Beaudry,et al.  Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization , 2007, Modern Pathology.

[35]  J. Witjes,et al.  Detection of TMPRSS2-ERG Fusion Transcripts and Prostate Cancer Antigen 3 in Urinary Sediments May Improve Diagnosis of Prostate Cancer , 2007, Clinical Cancer Research.

[36]  Amy Blase,et al.  PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. , 2007, Urology.

[37]  Leonard S. Marks,et al.  APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. , 2006, Clinical chemistry.

[38]  D. Bostwick,et al.  Prostate cancer detected by uPM3: radical prostatectomy findings , 2006, Modern Pathology.

[39]  M. Wirth,et al.  Quantitative multi‐gene expression profiling of primary prostate cancer , 2006, The Prostate.

[40]  H. Razvi,et al.  Expression of human telomerase reverse transcriptase, Survivin, DD3 and PCGEM1 messenger RNA in archival prostate carcinoma tissue. , 2006, The Canadian journal of urology.

[41]  Robert A Gardiner,et al.  Use of multiple biomarkers for a molecular diagnosis of prostate cancer , 2005, International journal of cancer.

[42]  Martina Tinzl,et al.  DD3PCA3 RNA analysis in urine--a new perspective for detecting prostate cancer. , 2004, European urology.

[43]  F. Saad,et al.  uPM3, a new molecular urine test for the detection of prostate cancer. , 2004, Urology.

[44]  Michael W Kattan,et al.  Evaluating a New Marker’s Predictive Contribution , 2004, Clinical Cancer Research.

[45]  L. Kiemeney,et al.  DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer , 2003 .

[46]  Michael W Kattan,et al.  Judging new markers by their ability to improve predictive accuracy. , 2003, Journal of the National Cancer Institute.

[47]  L. Kiemeney,et al.  DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. , 2002, Cancer research.

[48]  J. Schalken,et al.  A novel method for the determination of basal gene expression of tissue-specific promoters: An analysis of prostate-specific promoters , 2001, Cancer Gene Therapy.

[49]  M Bolla,et al.  EAU guidelines on prostate cancer. , 2001, European urology.

[50]  W. Isaacs,et al.  DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. , 1999, Cancer research.

[51]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[52]  A. Haese*,et al.  Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. , 2011, European urology.

[53]  Thomas Wiegel,et al.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. , 2011, European urology.

[54]  R. Autorino,et al.  Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3. , 2011, European urology.

[55]  J. Witjes,et al.  Predictive value of PCA3 in urinary sediments in determining clinico‐pathological characteristics of prostate cancer , 2010, The Prostate.

[56]  K. Pettersson,et al.  Quantitative real-time RT-PCR assay for PCA3. , 2008, Clinical biochemistry.